Proteon Therapeutics Inc. (NASDAQ:PRTO) – Research analysts at Oppenheimer Holdings boosted their FY2016 earnings per share estimates for shares of Proteon Therapeutics in a report issued on Monday. Oppenheimer Holdings analyst J. Olson now forecasts that the firm will post earnings per share of ($1.77) for the year, up from their previous forecast of ($1.83). Oppenheimer Holdings also issued estimates for Proteon Therapeutics’ Q4 2016 earnings at ($0.47) EPS, FY2017 earnings at ($2.04) EPS, FY2018 earnings at ($2.22) EPS, FY2019 earnings at $0.18 EPS and FY2020 earnings at $1.96 EPS.

Other research analysts also recently issued reports about the company. Maxim Group started coverage on Proteon Therapeutics in a research note on Thursday. They set a “buy” rating and a $19.00 target price on the stock. HC Wainwright started coverage on Proteon Therapeutics in a research note on Thursday, September 22nd. They set a “buy” rating and a $18.00 target price on the stock. Zacks Investment Research upgraded Proteon Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 12th. Cowen and Company started coverage on Proteon Therapeutics in a research note on Wednesday, October 19th. They set an “outperform” rating on the stock. Finally, Raymond James Financial Inc. upgraded Proteon Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a research note on Wednesday, October 26th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $20.33.

Proteon Therapeutics (NASDAQ:PRTO) opened at 8.80 on Thursday. Proteon Therapeutics has a 1-year low of $4.90 and a 1-year high of $16.48. The stock has a 50 day moving average price of $9.05 and a 200 day moving average price of $8.24. The company’s market cap is $145.92 million.

Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.03.

A number of hedge funds have recently bought and sold shares of PRTO. Spark Investment Management LLC purchased a new stake in Proteon Therapeutics during the third quarter valued at $107,000. Northern Trust Corp boosted its position in shares of Proteon Therapeutics by 0.3% in the third quarter. Northern Trust Corp now owns 13,125 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 42 shares during the period. TFS Capital LLC bought a new position in shares of Proteon Therapeutics during the second quarter valued at about $206,000. Paloma Partners Management Co bought a new position in shares of Proteon Therapeutics during the second quarter valued at about $234,000. Finally, Bridgeway Capital Management Inc. boosted its position in shares of Proteon Therapeutics by 211.2% in the second quarter. Bridgeway Capital Management Inc. now owns 36,835 shares of the biopharmaceutical company’s stock valued at $296,000 after buying an additional 25,000 shares during the period. Institutional investors and hedge funds own 51.54% of the company’s stock.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

5 Day Chart for NASDAQ:PRTO

Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.